BMEA241220C15000
- 0.65
- -0.01-1.52%
Biomea Fusion Newsroom
Scotiabank Sticks to Their Buy Rating for Biomea Fusion (BMEA)
H.C. Wainwright Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $40
Biomea Fusion Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Positive Buy Recommendation for Biomea Fusion Amid Promising Diabetes Treatment Developments in COVALENT-111 Phase 2 Trial
Express News | D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $128 Price Target
Biomea Fusion Announces Late-Breaker Oral Presentation Showing New Analysis From The Escalation Portion Of COVALENT-111 Presented At The 1st Annual Asian Conference On Innovative Therapies For Diabetes Management; Icovamenib Achieves A Mean Reduction...
Biomea Fusion's Icovamenib Shows Efficacy in Type 2 Diabetes Trial
We're A Little Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate
Biomea Fusion, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Express News | Biomea Fusion, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Press Release: Biomea Fusion, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Scotiabank Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $41
A Quick Look at Today's Ratings for Biomea Fusion(BMEA.US), With a Forecast Between $19 to $60
Express News | Biomea Fusion Inc - Preclinical Data Shows Bmf-219 Enhanced Effectiveness of GLP-1-Based Therapies
Express News | Biomea Fusion Inc - Phase II Study (Covalent-211), Combining Icovamenib With a GLP-1-Based Therapy, Planned to Begin in 2025
Biomea Fusion Shares Are Trading Lower. The Company Reported Q3 Financial Results.
Biomea Fusion Is Maintained at Equal-Weight by Barclays
EF Hutton Maintains Buy on Biomea Fusion, Maintains $128 Price Target
Express News | Biomea Fusion Inc. : Barclays Raises Target Price to $11 From $9
Biomea Fusion | 10-Q: Q3 2024 Earnings Report